T2-high asthma
MONDO:0956975A chronic asthma that is characterized by the pathophysiology phenotype combination (endotype) of early-onset allergic asthma, late-onset eosinophilic asthma, and aspirin-exacerbated respiratory disease.
49 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug shows promise in reversing lung damage from severe asthma
Disease control OngoingThis study tests whether benralizumab can improve lung structure and function in people with severe eosinophilic asthma who still have symptoms despite standard treatments. About 75 adults aged 18-70 will receive either the drug or a placebo for 48 weeks, followed by a 4-week che…
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New shot could tame asthma Flare-Ups
Disease control OngoingThis Phase 2 trial tests whether adding rademikibart (a shot) to standard care can help adults and teens with asthma and type 2 inflammation avoid hospital visits or needing more steroids during an attack. About 160 participants will receive either the drug or a placebo. The main…
Phase: PHASE2 • Sponsor: Connect Biopharm LLC • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Asthma breakthrough? new study tests cutting back on meds with benralizumab
Disease control OngoingThis Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New asthma drug shows promise in late-stage trial
Disease control OngoingThis study tests a new antibody drug (called 610) for adults with severe asthma that is not well controlled by standard inhalers. About 225 participants will receive either the drug or a placebo to see if it improves lung function and reduces asthma attacks over 52 weeks. The dru…
Phase: PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill could ease severe asthma attacks
Disease control OngoingThis Phase 3 trial tests dexpramipexole, an oral tablet, as an add-on treatment for people with eosinophilic asthma that is not well controlled. About 600 participants aged 12 and older will receive either the drug or a placebo for 24 weeks. The study measures improvements in lun…
Phase: PHASE3 • Sponsor: Areteia Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Real-world data on benralizumab for severe asthma: what happens outside clinical trials?
Knowledge-focused OngoingThis study looks back at medical records of 197 adults in Israel who started benralizumab for severe asthma between 2019 and 2024. Researchers will count how many asthma attacks (exacerbations) patients had before and after starting the drug. The goal is to see how well benralizu…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
35,000 asthma patients under the microscope: Real-World dupilumab use revealed
Knowledge-focused OngoingThis study looks at how dupilumab, a drug for severe asthma, is actually used by patients in France. Researchers will analyze health records of about 35,000 people to describe their characteristics, healthcare costs, and steroid use before and after starting the drug. The goal is…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Severe asthma drug may boost daily steps, study hopes
Knowledge-focused OngoingThis study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see i…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study digs into how mepolizumab changes nose bacteria and genes in asthma patients
Knowledge-focused OngoingThis study tracks 40 people with nasal polyps and severe asthma who are taking mepolizumab, a drug that reduces inflammation. Researchers collect nose, blood, and sputum samples before treatment and at 3, 6, and 12 months to see how the drug affects symptoms, nose bacteria, and g…
Sponsor: National and Kapodistrian University of Athens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Proteomics may unlock key clues to mepolizumab success in rare lung disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find biological markers in blood, saliva, and sputum that can predict how well patients with EGPA (a rare inflammatory disease) and severe asthma respond to the drug mepolizumab. Researchers will analyze proteins in these samples before and after treatment to u…
Phase: PHASE4 • Sponsor: Azienda Ospedaliero Universitaria di Cagliari • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
New breath test could replace painful lung scopes
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to see if a simple, non-invasive breathing test can accurately measure the acidity (pH) in the airways, which is often abnormal in lung diseases. Researchers will compare results from this breath test with standard methods in 150 healthy volunteers and people with…
Phase: PHASE2 • Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC